You are here: Industry Insights > Alzheimer's Disease

News List

Alzheimer’s Disease - Recent Advances in Treatment Neeta Ratanghayra
August 06, 2021
Alzheimer's disease (AD) is a neurodegenerative disease affecting millions of people globally.
ADUHELM: The First FDA Approved Therapy for Alzheimer’s Disease Since 2003 Lin Zhang
July 20, 2021
Aducanumab, known as ADUHELM, was co-developed by Biogen and Eisai and newly approved by the United States Food and Drug Administration (FDA) on June 7, 2021 (BLA 761178) under the provisions of accelerated approval regulations (21 CFR 601.41).
Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting PharmaSources.com
March 11, 2022
Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody...
Study identifies how COVID-19 linked to Alzheimer's disease-like cognitive impairment worldpharmanews
June 16, 2021
A new Cleveland Clinic-led study has identified mechanisms by which COVID-19 can lead to Alzheimer's disease-like dementia. The findings, published in Alzheimer's Research & Therapy, indicate an overlap between COVID-19 and brain changes common in ...
Qynapse to present clinical results of QyScore® for Alzheimer's Disease and Multiple Sclerosis at the 7th Congress of the European Academy of Neurology prnasia
June 16, 2021
QYNAPSE Inc., a medical technology company commercializing the most advanced artificial intelligence neuroimaging platform, today announced it will present clinical data on QyScore® for Alzheimer's disease and multiple sclerosis at the 7th Congress of ...
Galimedix Accelerating Development of Its Next-Generation Oral Anti-Amyloid Beta Drug GAL-201 for Alzheimer's Disease prnasia
June 16, 2021
Galimedix, Inc. today announced an accelerated program for its promising oral small molecule GAL-201 targeting amyloid beta oligomers, the same target addressed by Biogen's ADUHELM™ approved earlier this month.
Soterix Medical Expands Clinical Trials for Alzheimer's Disease, Cognitive Impairment americanpharmaceuticalreview
December 31, 2020
Soterix Medical has reported expanded clinical trials of its proprietary neuromodulation technologies for Alzheimer's disease and Mild Cognitive Impairment.
Athira Pharma Initiates Patient Dosing for ATH-1017 Trial for Alzheimer’s Disease americanpharmaceuticalreview
December 17, 2020
Athira Pharma announced patient dosing has begun in ACT-AD, a Phase 2 randomized, placebo-controlled study of ATH-1017 in patients with mild-to-moderate Alzheimer's disease.
Molecular Stethoscope Announces Completion and Publication of its Alzheimer's Disease Study in Science Advances prnasia
December 14, 2020
Molecular Stethoscope, Inc., a precision medicine biotechnology company, announces publication of a human proof-of-concept study for Alzheimer's Disease using its proprietary cell-free messenger RNA (cf-mRNA)-Artificial Intelligence Technology Platform.
GemVax & KAEL reports further positive data from GV1001 Phase II Alzheimer's Disease trial prnasia
November 24, 2020
GemVax & KAEL Co., Ltd. a clinical stage company developing a novel peptide drug based on telomerase modification has released further positive data at the Korean Dementia Association's Fall Conference from a Phase II trial in Alzheimer's disease of ...

Previous page 1 2 3 4 Next page